Zealand Pharma CEO hails AI protein deal with Generate Biomedicines

Demant CEO Søren Nielsen says AI-powered hearing aids have to strike the right balance when it comes to handling noise. His reasoning is that humans are good at combining what they see with what they hear and using that to form a picture of what they want to listen to. The piece is behind a subscription, and only that quote and the headline are available here, so the rest of his argument is not covered.

Alongside it, the page carries a few other Nordic life-science items, again only as fragments. Peter Aksel Villadsen is leaving GN Hearing to join Cellular Intelligence. That company acquired a Parkinson's program from Novo Nordisk earlier this year and set up its European headquarters in Copenhagen. A headline describes him as the former GN executive who will lead the Nordic expansion of the AI cell-therapy company that took over the Novo program.

Other snippets say Lundbeck plans to consolidate all of its API production at its Danish manufacturing facility in Lumsås. Zealand Pharma, led by CEO Adam Steensberg, released new data on Wednesday, though the details are not given. A headline also refers to Zealand Pharma's CEO praising an AI protein deal with Generate Biomedicines, with no terms stated.

The common thread is the growing role of AI in Danish and Nordic health and pharma, from hearing devices to protein design and cell therapy, along with leadership moves and manufacturing decisions in the sector.